Seonix Bio Announces US Launch of SightScore, the First Commercially Available Clinical Polygenic Risk Score Testing Service for Glaucom

“I am incredibly pleased that we are able to make SightScore clinically available in the U.S., marking a significant advancement in the fight against glaucoma,” said Nick Haan, CEO, Seonix Bio.